CD20, encoded by MS4A1 , is one of the earliest and most extensively used immunotherapeutic targets in B ‐ cell malignancies and the mechanisms underlying resistance remain poorly understood.
A. Guijosa, N. Tsakmaklis, S. Dhe-Paganon et al.· HemaSphere· 0 citations
AdaptiveFlow enables drug discovery at unprecedented scale and supports the development of AI-driven methods, and identifies nanomolar inhibitors of two disease-relevant targets, ferroptosis suppressor protein 1 and poly(ADP-ribose) polymerase 1.
Domiziana Cecchini, AkshatKumar Nigam, Ming Tang et al.· Nature Biotechnology· 1 citation
Small molecules that modulate protein complexes have transformed cell biology and oncology, yet few chemical starting points exist to probe protein-protein interactions. To expand this space, we developed molecular COUPLrs, elaborated small molecules flanked by two cysteine-reactive warheads. Using CONNECT, an integrat...
Diane Yang, S. Harry, H. Chong et al.· Cancer Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.